Ionis falls after AstraZeneca-partnered drug fails late-stage heart disease trial

AstraZeneca

09/07/2026 10:29

** Ionis Pharmaceuticals IONS.O slides 21.8% premarket to $67.80
** Co's nerve disease drug Wainua, made in partnership with AstraZeneca AZN.L fails to meet main goal of reducing cardiovascular deaths and recurring heart problems in a late-stage trial
** Setback dents what analysts predicted could be a $2 billion peak-sales opportunity for the drug
** Shares of Alnylam Pharmaceuticals ALNY.O and BridgeBio Pharma BBIO.O which have approved drugs for the disease, are up 15.3% and 9.9% respectively
** As of last close, IONS up 6.7% YTD

 (Reporting by Sudeshna Ghoshal in Bengaluru)
 ((Sudeshna.Ghoshal@thomsonreuters.com;))